During the corresponding time, Alimera Sciences Inc recorded a revenue increase by 52.92 % year on year, sequentially revenue grew by 15.5 %. While revenue at the Alimera Sciences Inc's corporate clients
Alimera Sciences Inc's Comment on Sales, Marketing and Customers
The company generated revenues from both U.S. and international markets. In the U.S., two large pharmaceutical distributors accounted for 70% and 63% of consolidated product revenues in 2023 and 2022, respectively. These distributors maintain inventories of ILUVIEN and YUTIQ and supply physician offices, pharmacies, and hospitals. Internationally, the company markets ILUVIEN directly to hospitals, clinics, and pharmacies. In other foreign countries, partnering distributors maintain inventory and sell to their customers, which include physician offices, pharmacies, hospitals, and clinics. The company competes globally with major pharmaceutical, specialty pharmaceutical, and biotechnology companies. Competitors for diabetic macular edema (DME) treatments include Eylea (marketed by Regeneron in the U.S. and Bayer in the European Economic Area), Vabysmo (marketed by Genentech), Avastin, and Lucentis (marketed by Genentech, a Roche company, in the U.S. and Novartis elsewhere).
Alimera Sciences Inc’s Comment on Sales, Marketing and Customers
The company generated revenues from both U.S. and international markets. In the U.S., two large pharmaceutical distributors accounted for 70% and 63% of consolidated product revenues in 2023 and 2022, respectively. These distributors maintain inventories of ILUVIEN and YUTIQ and supply physician offices, pharmacies, and hospitals. Internationally, the company markets ILUVIEN directly to hospitals, clinics, and pharmacies. In other foreign countries, partnering distributors maintain inventory and sell to their customers, which include physician offices, pharmacies, hospitals, and clinics. The company competes globally with major pharmaceutical, specialty pharmaceutical, and biotechnology companies. Competitors for diabetic macular edema (DME) treatments include Eylea (marketed by Regeneron in the U.S. and Bayer in the European Economic Area), Vabysmo (marketed by Genentech), Avastin, and Lucentis (marketed by Genentech, a Roche company, in the U.S. and Novartis elsewhere).
Sources:
Alimera Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Alimera Sciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Alimera Sciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
65.03 %